La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Enfusion Crescita futura

Future criteri di controllo 5/6

Enfusion prevede che gli utili e i ricavi cresceranno rispettivamente di 66.8% e 16.4% all'anno. Si prevede che l'EPS crescerà di 61% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 27.9% in 3 anni.

Informazioni chiave

66.8%

Tasso di crescita degli utili

61.0%

Tasso di crescita dell'EPS

Software crescita degli utili	15.7%
Tasso di crescita dei ricavi	16.4%
Rendimento futuro del capitale proprio	27.9%
Copertura analitica	Good
Ultimo aggiornamento	07 Aug 2024

Aggiornamenti recenti sulla crescita futura

Enfusion, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Aug 11

Recent updates

Investors Appear Satisfied With Enfusion, Inc.'s (NYSE:ENFN) Prospects As Shares Rocket 28%

Dec 02

Enfusion: Still Bullish Considering Q3 EBITDA Beat

Nov 08

Why Enfusion, Inc. (NYSE:ENFN) Could Be Worth Watching

Oct 31

Enfusion Faces Cross-Currents In Investment Management Software Market

Aug 24

Enfusion, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Aug 11

Enfusion: Multiple Catalysts

Jun 20

Enfusion, Inc.'s (NYSE:ENFN) Intrinsic Value Is Potentially 32% Above Its Share Price

Mar 08

Here's Why We're Not At All Concerned With Enfusion's (NYSE:ENFN) Cash Burn Situation

Feb 08

Enfusion brings on Shift4 Payments' Brad Herring as CFO

Dec 19

Enfusion Expands Offerings As Revenue Growth Decelerates

Oct 31

Enfusion, Inc. (NYSE:ENFN) Shares Could Be 49% Below Their Intrinsic Value Estimate

Oct 18

Enfusion gains after takeover report

Aug 31

Enfusion gets new interim CEO

Aug 22

Here's Why We're Not At All Concerned With Enfusion's (NYSE:ENFN) Cash Burn Situation

Aug 12

Enfusion: A Compelling Financial SaaS Company

Jun 24

Estimating The Fair Value Of Enfusion, Inc. (NYSE:ENFN)

May 10

Previsioni di crescita degli utili e dei ricavi

NYSE:ENFN - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	283	44	56	69	5
12/31/2025	242	30	37	50	8
12/31/2024	205	17	23	34	8
6/30/2024	188	3	17	28	N/A
3/31/2024	182	2	16	26	N/A
12/31/2023	175	6	16	26	N/A
9/30/2023	169	6	17	27	N/A
6/30/2023	163	6	15	22	N/A
3/31/2023	157	3	12	19	N/A
12/31/2022	150	-9	6	14	N/A
9/30/2022	142	-208	-7	1	N/A
6/30/2022	132	-207	-18	-9	N/A
3/31/2022	121	-200	-14	-5	N/A
12/31/2021	112	-188	-8	0	N/A
9/30/2021	103	-1	-13	-5	N/A
6/30/2021	93	2	-3	3	N/A
3/31/2021	85	3	-7	-1	N/A
12/31/2020	80	4	-3	2	N/A
12/31/2019	59	13	8	12	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di ENFN ( 66.8% all'anno) è superiore al tasso di risparmio ( 2.5% ).

Guadagni vs Mercato: Si prevede che gli utili di ENFN ( 66.8% all'anno) cresceranno più rapidamente del mercato US ( 15.1% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di ENFN cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di ENFN ( 16.4% all'anno) crescerà più rapidamente del mercato US ( 8.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di ENFN ( 16.4% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di ENFN sarà elevato tra 3 anni ( 27.9 %)

Enfusion Crescita futura

Future criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates increase by 51%

Consensus EPS estimates fall by 38%

Consensus EPS estimates fall by 20%, revenue upgraded

Consensus EPS estimates fall by 32%

Enfusion, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Price target decreased by 7.0% to US$10.43

Recent updates

Enfusion: Growth Should Accelerate In Coming Quarters

Investors Can Find Comfort In Enfusion's (NYSE:ENFN) Earnings Quality

Consensus EPS estimates increase by 51%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Shareholder dilution

Enfusion, Inc. Introduces the Next Phase of Portfolio Workbench, Empowering Asset Managers with Increased Efficiency and Flexibility

New minor risk - Shareholder dilution

Enfusion, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Chief People Officer recently sold US$234k worth of stock

Chief People Officer notifies of intention to sell stock

Enfusion: Expectations Of Faster Growth And Higher Margins Justify A Buy Rating

New minor risk - Shareholder dilution

Chief People Officer recently sold US$325k worth of stock

Chief People Officer notifies of intention to sell stock

Consensus EPS estimates fall by 38%

New minor risk - Profit margin trend

First quarter 2024 earnings: EPS misses analyst expectations

Enfusion, Inc., Annual General Meeting, Jun 13, 2024

Enfusion, Inc. to Report Q1, 2024 Results on May 09, 2024

Consensus EPS estimates fall by 20%, revenue upgraded

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS misses analyst expectations

Is Now An Opportune Moment To Examine Enfusion, Inc. (NYSE:ENFN)?

New minor risk - Shareholder dilution

Now 20% undervalued after recent price drop

Capital Allocation Trends At Enfusion (NYSE:ENFN) Aren't Ideal

Enfusion, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Now 22% undervalued

New minor risk - Shareholder dilution

Enfusion, Inc. Elevates Valeria Gutowski to Chief Accounting Officer

Enfusion: Product Is Sticky And Industry Is Huge

Calculating The Fair Value Of Enfusion, Inc. (NYSE:ENFN)

CEO & Director recently sold US$1.0m worth of stock

New minor risk - Shareholder dilution

CEO & Director recently sold US$1.5m worth of stock

CEO & Director notifies of intention to sell stock

Investors Appear Satisfied With Enfusion, Inc.'s (NYSE:ENFN) Prospects As Shares Rocket 28%

Managing Partner recently sold US$9.9m worth of stock

Enfusion, Inc. Appoints Neal Pawar as Chief Operating Officer, Effective November 27, 2023

Third quarter 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 32%

Enfusion: Still Bullish Considering Q3 EBITDA Beat

Why Enfusion, Inc. (NYSE:ENFN) Could Be Worth Watching

Enfusion, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Shareholder dilution

Enfusion Faces Cross-Currents In Investment Management Software Market

Enfusion, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Price target decreased by 7.0% to US$10.43

Enfusion, Inc. Appoints Andi Woolass as Head of Partnerships and Alliances for EMEA

Enfusion Reportedly Draws Takeover Interest from Private Equity, Irenic Capital

Enfusion: Multiple Catalysts

Now 21% undervalued after recent price drop

Price target decreased by 7.1% to US$11.21

Chief Technology Officer recently sold US$396k worth of stock

Chief Technology Officer notifies of intention to sell stock

Now 21% undervalued after recent price drop

Chief Technology Officer recently sold US$126k worth of stock

Chief Technology Officer notifies of intention to sell stock

First quarter 2023 earnings: EPS exceeds analyst expectations

Now 22% undervalued after recent price drop

Insider recently sold US$20m worth of stock

Full year 2022 earnings released: US$0.15 loss per share (vs US$2.26 loss in FY 2021)

Enfusion, Inc.'s (NYSE:ENFN) Intrinsic Value Is Potentially 32% Above Its Share Price

Enfusion, Inc. to Report Q4, 2022 Results on Mar 07, 2023

Here's Why We're Not At All Concerned With Enfusion's (NYSE:ENFN) Cash Burn Situation

Enfusion, Inc. Names Michael Spellacy as Board Chair and Non-Executive Director

Price target decreased to US$12.80

Enfusion, Inc. Names Oleg Movchan as Chief Executive Officer

Enfusion, Inc. Appoints Brad Herring as Chief Financial Officer